Solara Active Pharma Sciences Ltd

Know More
NSEBSE

477.7013.70 (2.95%)

03:53 PM,21st Feb 2024

477.6013.40 (2.89%)

04:01 PM,21st Feb 2024

BSE : 541540

NSE : SOLARA

Sector : Health care

ISIN Code : INE624Z01016

  • NSE
  • BSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: Feb 21 2024 | 04:01 PM IST

Market Cap (₹ Cr)

1719

Turnover (₹ Cr)

8.62

Volume (Shares)

1805506

Face Value

10

52-WK High

495.00

52-WK High Date

21 Feb 2024

52-WK Low

286.00

52-WK Low Date

01 Nov 2023

All Time High

1859.95

All Time High Date

19 May 2021

All Time Low

134.50

All Time Low Date

12 Jul 2018

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd is a Public Limited Company incorporated in February 23 2017 under the provisions of Companies Act 2013 to undertake business in manufacturing production processing formulating sale import export merchandising distributing trading of and dealing in active pharmaceutical ingredients (APIs). The Company has six APIs manufacturing plants located in Ambernath Mangalore Mysore Puducherry Vishakhapatnam and Cuddalore with a capacity of over 2000 kilo litres and two R&D Centres in Chennai and Bangalore. The business is spread across 75 countries globally with extensive operations in key markets of North America Europe Japan South Korea the Middle East and North Africa.The Company offer rich basket of niche high-value products for global markets. The Company has developed 80+ commercial APIs predominantly in anthelmintic anti-malarias anti-infective neuromuscular insomnia and anti-psychotic hyperkalemia segments among others. It also reinforce entry barriers to competition and build strong intrinsic value through market specific launches. Apart from this the Solara Active has two research and development units - in Bengaluru and Chennai - equipped with state-of-the-art facilities and a pipeline of 25+ products at different stages of development. These drugs primarily deal with anthelmintic anti-malarias beta blockersmuscle relaxants novel oral anticoagulants anti-infective and other niche segments.The Company's manufacturing facilities enjoy regulatory approvals from the United States Food and Drug Administration (USFDA); European Directorate for the Quality of Medicines (EDQM); Korea Food & Drug Administration (KFDA) - South Korea; Euro Zone - Good Manufacturing Practice (EUGMP) - Danish World Health Organization (WHO) - Geneva; Medicines and Healthcare products RegulatoryAgency (MHRA); Federal Commission for the Protection against Sanitary Risk (Cofepris) - Mexico; Therapeutic Goods Administration (TGA)- Australia; Pharmaceuticals and Medical Devices Agency (PMDA) - Japan.During the year the Company's wholly owned subsidiary Strides Chemicals Private Limited (Strides Chemicals) was amalgamated with the Company. The Honourable National Company Law Tribunal Mumbai Bench approved the Scheme of Amalgamation of Strides Chemicals with Company on December 20 2019. Accordingly the Company has fixed effective date for the Scheme is February 01 2020. The appointed date for scheme is September 01 2018. The Company has completed filing of necessary documents for giving effect to the Scheme. Consequent to amalgamation the entire equity shares held by Company in Strides Chemicals stands cancelled.The Board of Directors of Company at its meeting held on April 09 2021 have approved Scheme of Amalgamation for merger of Aurore Life Science Private Limited Empyrean Lifesciences Private Limited and Hydra Active Pharma Sciences Private Limited (Transferor Companies) into the Company (Transferee Company) in terms of Section 230 to 232 of the Companies Act 2013. The Scheme is subject to necessary statutory and regulatory approvals including the approvals of National Company Law Tribunal the shareholders and creditors of each of the companies. The Appointed Date for the said Scheme of Amalgamation is April 01 2021 or such other date as may be agreed between the Transferor Company and Transferee Company and approved by National Company Law Tribunal.The Company's new Greenfield plant situated at SEZ unit Plot No.:3B3C3D Part 2 and 2A-1 APIIC APSEZ Atchutapuram Village Rambilli Mandal Visakhapatnam - 531011 Andhra Pradesh has commenced commercial production in 2021.The Board at its meeting held on February 3 2021 has approved to acquire 487000 additional share capital in Sequent Penems Private Limited subsidiary company of Solara. Subsequent to year end the said transaction is completed and Sequent Penems Private Limited is wholly owned subsidiary of Company with effect from April 27 2021.The achievements received by the Company in FY 2020-21 were as follows: The Ambernath facility received Certificate of Merit from National Safety Council Maharashtra for `Lowest Average Accident Frequency Rate'. They improved EcoVadis Score from 31 to 47 and was awarded a bronze medal in recognition of Sustainability achievement. The Mangalore site of company was certified for ISO 14001 and ISO 45001. Besides they conducted a Red Tag Event to identify unsafe conditions and acts to make workplace injury nd incident free. All employees and contractors actively participated in the event..

Solara Active Pharma Sciences Ltd - Key Fundamentals

PARAMETER VALUES
Market Cap (₹ Cr)

1719

EPS - TTM (₹) [C]

0.00

P/E Ratio (X) [C]

1.18

Face Value (₹) 10
Latest Dividend (%)30.00
Latest Dividend Date 18 Aug 2021
Dividend Yield (%) 0.65
Book Value Share (₹) [C]406.55
P/B Ratio (₹) [C]1.18
[*C] Consolidated [*S] Standalone

Funds Owing this Stock

Scheme Name Amount Invested ( ₹ Cr ) No Of Shares Net Asset (%)
Aditya Birla SL Flexi Cap Fund (G) 16.14 420000 0.08
Aditya Birla SL Flexi Cap Fund (IDCW) 16.14 420000 0.08
Aditya Birla SL Flexi Cap Fund - Direct (IDCW) 16.14 420000 0.08
Aditya Birla SL Flexi Cap Fund - Direct (G) 16.14 420000 0.08
Aditya Birla SL Midcap Fund - (G) 5.00 130000 0.10
Aditya Birla SL Midcap Fund - (IDCW) 5.00 130000 0.10
Aditya Birla SL Midcap Fund - Direct (IDCW) 5.00 130000 0.10
Aditya Birla SL Midcap Fund - Direct (G) 5.00 130000 0.10
Aditya Birla SL Manufacturing Equity Fund (G) 2.50 65000 0.30
Aditya Birla SL Manufacturing Equity Fund (IDCW) 2.50 65000 0.30

Load more

Research Reports

Date BrokerActionPrices(Rs)Report
Data Not Found

Stock Strength

Today's Low/High

467.00

495.00

Week Low/High

350.00

495.00

Month Low/High

350.00

495.00

Year Low/High

286.00

495.00

All time Low/High

133.50

1860.00

Share Price Returns

Period BSENSE SENSEXNIFTY
1 Week32.93%32.29%1.110.98%
1 Month16.47%16.53%1.682.24%
3 Month42.51%42.81%10.1511.48%
6 Month35.79%35.59%11.3613.72%
1 Year28.43%28.45%19.7023.72%
3 Year-65.10%-65.15%42.7147.21%

Company Info

Company Information

Chairman (Non-Executive) : Deepak Vaidya

Managing Director : Jitesh Devendra

Executive Director (Fin) & CFO : Hariharan Subramaniam

Independent Director : Nirmal P Bhogilal

Independent Director : RAJAGOPALAN RAMAKRISHNAN

Independent Director : Kausalya Santhanam

Company Secretary : S Murali Krishna

Addtnl Independent Director : Ronald Tjeerd De Vries

Registered Office: 201 Devavrata Sector 17 Vashi, Navi Mumbai,Mumbai,Maharashtra-400703 Ph: 91-22-27892924

Email:investors@solara.co.in

URL:http://www.solara.co.in